Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Paul D. Harker-Murray"'
Publikováno v:
Advances in Oncology. 3:67-76
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e5052e595514a7daf6c5db9e4688026
https://doi.org/10.1016/j.yao.2023.01.016
https://doi.org/10.1016/j.yao.2023.01.016
Autor:
Raymond B. Mailhot Vega, Paul D. Harker-Murray, Christopher J. Forlenza, Peter Cole, Kara M. Kelly, Sarah A. Milgrom, Rahul R. Parikh, David C. Hodgson, Sharon M. Castellino, Justine Kahn, Kenneth B. Roberts, Louis S. Constine, Bradford S. Hoppe
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b8a69328bab372c80d34c94685e6db0
https://doi.org/10.1016/j.ijrobp.2023.04.022
https://doi.org/10.1016/j.ijrobp.2023.04.022
Autor:
Olivia M. T. Davies, John M. Astle, Paul D. Harker‐Murray, Karolyn A. Wanat, Valerie M. Carlberg
Publikováno v:
Pediatric Dermatology. 40:367-368
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1467aa6fd097734d67a1b1457552a6ca
https://doi.org/10.1111/pde.15167
https://doi.org/10.1111/pde.15167
Autor:
Lauren J. Miller, Vasiliki Leventaki, Paul D. Harker-Murray, Holli M. Drendel, Kathleen M. Bone
Publikováno v:
Cancer genetics.
The KMT2A::AFF3 fusion, t(2;11)(q11.2;q23.2), is a very rare fusion occurring in pediatric B-cell acute lymphoblastic leukemia (B-ALL). Our patient is a 2-year-old male who presented with three weeks of intermittent fever. Bone marrow biopsy showed 8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a16e3138a103328eaac0507a239ac447
https://pubmed.ncbi.nlm.nih.gov/34995897
https://pubmed.ncbi.nlm.nih.gov/34995897
Autor:
Paul D, Harker-Murray, Richard A, Drachtman, David C, Hodgson, Allen Russell, Chauvenet, Kara M, Kelly, Peter David, Cole
Publikováno v:
Pediatric bloodcancer. 61(4)
Risk-adapted, response-based therapies for pediatric Hodgkin lymphoma have resulted in 5-year survival exceeding 90%. Although high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) are considered standard for most pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d4e3618be13b9f6c1f667db96450c07f
https://pubmed.ncbi.nlm.nih.gov/24504790
https://pubmed.ncbi.nlm.nih.gov/24504790